A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases

Journal of the American Chemical Society

Volumn 129, Issue 31, 2007, Pages 9594-9595

  Li, Weiwei ^a   Blankman, Jacqueline L ^a   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROLASE INHIBITOR;

ARTICLE; COVALENT BOND; FLUORESCENCE; IC 50; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEOMICS;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HYDROLASES; MOLECULAR STRUCTURE; PROTEOMICS;

EID: 34547789923     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja073650c     Document Type: Article

References (24)

1. (a) Lander, E. S.; et al. Nature 2001, 409, 860-921.
2. (b) Venter, J. C.; et al. Science 2001, 291, 304-51.
3. (a) Thornberry, N. A.; Weber, A. E. Curr. Top. Med. Chem. 2007, 7, 557-68.
4. (b) Jann, M. W. Pharmacotherapy 2000, 20, 1-12.
5. (c) Nelson, R. H.; Miles, J. M. Exp. Opin. Pharmacother. 2005, 6, 2483-91.
6. (d) Srivastava, S.; Goswami, L. N.; Dikshit, D. K. Med. Res. Rev. 2005, 25, 66-92.
7. Walsh, C. T. Enzymatic Reaction Mechanisms; W.H. Freeman and Company: New York, 1979.
8. (a) Liu, Y.; Patricelli, M. P.; Cravatt, B. F. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14694-9.
9. (b) Kidd, D.; Liu, Y.; Cravatt, B. F. Biochemistry 2001, 40, 4005-15.
10. (c) Patricelli, M. P.; Giang, D. K.; Stamp, L. M.; Burbaum, J. J. Proteomics 2001, 1, 1067-71.
11. (a) Jessani, N.; Liu, Y.; Humphrey, M.; Cravatt, B. F. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10335-40.
12. (b) Milner, J. M.; Kevorkian, L.; Young, D. A.; Jones, D.; Wait, R.; Donell, S. T.; Barksby, E.; Patterson, A. M.; Middleton, J.; Cravatt, B. F.; Clark, I. M.; Rowan, A. D.; Cawston, T. E. Arthritis Res. Ther. 2006, 8, R23.
13. (c) Barglow, K. T.; Cravatt, B. F. Chem. Biol. 2004, 11, 1523-31.
14. Leung, D.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Nat. Biotechnol. 2003, 21, 687-91.
15. Saghatelian, A.; Trauger, S. A.; Want, E. J.; Hawkins, E. G.; Siuzdak, G.; Cravatt, B. F. Biochemistry 2004, 43, 14332-9.
16. Chiang, K. P.; Niessen, S.; Saghatelian, A.; Cravatt, B. F. Chem. Biol. 2006, 13, 1041-50.
17. (a) Desai, A.; Grossberg, G. Exp. Opin. Pharmacother. 2001, 2, 653-66.
18. (b) Piomelli, D.; Tarzia, G.; Duranti, A.; Tontini, A.; Mor, M.; Compton, T. R.; Dasse, O.; Monaghan, E. P.; Parrott, J. A.; Putman, D. CNS Drug Rev. 2006, 12, 21-38.
19. The selective distribution of ABHD6 to the membrane proteome is consistent with hydropathy plots, which predict that the enzyme contains a single transmembrane domain from amino acids 8-24.
20. Jessani, N.; Niessen, S.; Wei, B. Q.; Nicolau, M.; Humphrey, M.; Ji, Y.; Han, W.; Noh, D. Y.; Yates, J. R., 3rd; Jeffrey, S. S.; Cravatt, B. F. Nat. Methods 2005, 2, 691-7.
21. A handful of other SHs showed 30-40% lower spectral counts in 70-treated samples (e.g., FAAH, BAT5, AChE), but none of these differences were statistically significant. Recombinant forms of these enzymes were not inhibited by up to 100 μM of 70 (Supporting Figure 5).
22. Maier, S.; Staffler, G.; Hartmann, A.; Hock, J.; Henning, K.; Grabusic, K.; Mailhammer, R.; Hoffmann, R.; Wilmanns, M.; Lang, R.; Mages, J.; Kempkes, B. J. Virol. 2006, 80, 9761-71.
23. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem., Int. Ed. 2001, 40, 2004-21.
24. Alexander, J. P.; Cravatt, B. F. Chem. Biol. 2005, 12, 1179-87.